Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 16/20 | 0.70 |
| ▸ | AVPR1A | P37288 | 14/20 | 0.70 |
| ▸ | OXTR | P30559 | 1/20 | 0.56 |
| ▸ | AVPR1B | P47901 | 4/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8204092 | 0.90 | AVPR2 (0.74) | AVPR2AVPR1AOXTRAVPR1B | |
| Hydrochloric Acid SCHEMBL6993733 | 0.89 | AVPR2 (0.73) | AVPR2AVPR1AOXTRAVPR1B | |
| Conivaptan SCHEMBL49815 | 0.82 | AVPR2 (1.00) | AVPR2AVPR1AOXTRAVPR1B | |
| SCHEMBL6991859 | 0.82 | AVPR1A (0.72) | AVPR2AVPR1AOXTRAVPR1B | |
| Conivaptan SCHEMBL28043077 | 0.81 | AVPR2 (0.98) | AVPR2AVPR1AOXTRAVPR1B | |
| Conivaptan SCHEMBL1649913 | 0.81 | AVPR2 (0.97) | AVPR2AVPR1AOXTRAVPR1B | |
| SCHEMBL17471541 | 0.79 | AVPR2 (0.68) | AVPR2AVPR1AOXTRAVPR1B | |
| SCHEMBL6619403 | 0.79 | AVPR2 (0.65) | AVPR2AVPR1AOXTRAVPR1B | |
| Conivaptan SCHEMBL4625101 | 0.77 | AVPR2 (0.75) | AVPR2AVPR1AOXTRAVPR1B | |
| Conivaptan SCHEMBL29406590 | 0.77 | AVPR2 (0.75) | AVPR2AVPR1AOXTRAVPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101782-B2 | Drug hybrid of rivastigmine or physostigmine with tranylcypromine, amoxapine, desipramine, nortriptyline, protriptyline, fluoxetine, fluvoxamine, paroxetine, duloxetine, betahistine, amlodipine, proylhexedrine, rimantadine, desloratadine; Alzheimer's disease; Parkinson's disease, impairment in memory | COLUCID PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101782-B2 | Drug hybrid of rivastigmine or physostigmine with tranylcypromine, amoxapine, desipramine, nortriptyline, protriptyline, fluoxetine, fluvoxamine, paroxetine, duloxetine, betahistine, amlodipine, proylhexedrine, rimantadine, desloratadine; Alzheimer's disease; Parkinson's disease, impairment in memory | COLUCID PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20080261950-A1 | Compounds that inhibit cholinesterase | COLUCID PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080261950-A1 | Compounds that inhibit cholinesterase | COLUCID PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261950-A1 | Compounds that inhibit cholinesterase | ACHE, BCHE, CHAT | AVPR2 3205/4885AVPR1A 3030/4885OXTR 2380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.